Back to search

Boston University

Targeted use of camptothecin as a specific pharmacological agent for the treatment of triple negative breast cancer

Abstract

dc:description.abstract

Triple negative breast cancer (TNBC) accounts for 15 to 20% of all new breast cancers diagnosed in the United States. This figure increases to greater than 30% in minority populations. Currently, targeted therapeutic options are not available for TNBC, thus resulting in the use of general chemotherapeutics and lower survival rates for those afflicted with the disease. Camptothecin and its structural analogues (CPTs) are specific, reversible inhibitors of topoisomerase I (topoi), and have recently shown promise in the treatment ofTNBC, with a response rate of nearly 40%. CPTs are targeted drugs, but only effective within a subset of cancer patient populations. In order to understand the regulation of topoi upon CPT administration and elucidate the resistance mechanism, we isolated a topoi interacting protein complex. We further investigated the role of proteins associated with topoi, and have determined that: (I) following CPT administration, topoi is phosphorylated at serine 10 (S10) by the DNA-PK/Ku-70/Ku-80 complex, (II) S10 phosphorylation ensures the ubiquitination oftopoi by the BRCA1/BARD1 heterodimer, (Ill) topoi is subsequently degraded by the ubiquitin-proteasomal pathway (UPP), and (IV) the rate oftopoi degradation determines the cellular response to CPT. In summary, BRCA1/BARD1 E3 ligase activity leads to the ubiquitination and rapid degradation of to poi, conferring cellular resistance to CPT. Phosphorylation levels of S10 on topol correlates to the rate of topol degradation, thus can be used as a predictive biomarker for CPT response. Taken together, CPT can be an effective treatment for a subset of the TNBC patient population.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Molecular Medicine
Grantor dc:publisher
Boston University
Year dc:date.issued
2013

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Shah, Ankur K.

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Dc Identifier Other
(ALMA)contemp

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Shah, Ankur K.. Targeted use of camptothecin as a specific pharmacological agent for the treatment of triple negative breast cancer. doctoral thesis, Boston University, 2013. https://hdl.handle.net/2144/12846